Journal of internal medicine
-
Randomized Controlled Trial Multicenter Study
Roxadustat reduces left ventricular mass index compared to rHuEPO in haemodialysis patients in a randomized controlled trial.
Left ventricular hypertrophy (LVH) is highly prevalent in haemodialysis (HD) patients and is associated with an increased risk of death. Roxadustat and recombinant human erythropoietin (rHuEPO, abbreviated as EPO) are the main treatment strategies for renal anaemia in HD patients, but it has not been clear whether there is a difference in their effect on LVH. ⋯ Compared to EPO, roxadustat is more helpful in the regression of LVH in HD patients.
-
Multicenter Study
Clinical presentation, course, and prognosis of patients with mixed connective tissue disease: A multicenter retrospective cohort.
The objective of this study is to better characterize the features and outcomes of a large population of patients with mixed connective tissue disease (MCTD). ⋯ This study shows that MCTD is a distinct entity that can be classified using either Kasukawa or Sharp criteria, and that only 25.8% of patients progress to a dCTD during follow-up.
-
Multicenter Study
Prevalence and prognostic value of electrocardiographic abnormalities in hypokalemia: A multicenter cohort study.
Hypokalemia is common in hospitalized patients and associated with ECG abnormalities. The prevalence and prognostic value of ECG abnormalities in hypokalemic patients are, however, not well established. ⋯ ECG abnormalities were common in hypokalemic patients, but they are poor prognostic markers for short-term adverse events under the current standard of care.
-
Multicenter Study
Minimal hepatic encephalopathy is associated with a higher risk of overt hepatic encephalopathy and poorer survival.
Minimal hepatic encephalopathy (MHE) is a frequent complication in patients with liver cirrhosis. Its impact on predicting the development of overt hepatic encephalopathy (OHE) and survival has not been studied in large multicenter studies. ⋯ This large multicenter study demonstrates that screening for MHE is a useful tool for predicting OHE and poorer survival.
-
Patients with relapsed or refractory acute myeloid leukemia (R/R AML) and FLT3-internal tandem duplication (FLT3-ITD) respond infrequently to salvage chemotherapy. ⋯ The sorafenib plus VAH regimen was well tolerated and highly active against R/R AML with FLT3-ITD. This regimen may be a suitable therapeutic option for this population, but larger population trials are needed to be explored.